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The successful transmission of dengue virus from a human host to a mosquito vector
requires a complex set of factors to align. It is becoming increasingly important to improve
our understanding of the parameters that shape the human to mosquito component of the
transmission cycle so that vaccines and therapeutic antivirals can be fully evaluated and
epidemiological models refined. Here we describe these factors, and discuss the biological
and environmental impacts and demographic changes that are influencing these dynam-
ics. Specifically, we examine features of the human infection required for the mosquito
to acquire the virus via natural blood feeding, as well as the biological and environmental
factors that influence a mosquito’s susceptibility to infection, up to the point that they are
capable of transmitting the virus to a new host.
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INTRODUCTION
THE GLOBAL DENGUE BURDEN
The medical (1) and economic (2–7) burden of dengue is large; a
recent probabilistic estimate suggested 100 million symptomatic
cases occurred in 2010 (8). Human travel patterns are chang-
ing, and there is far more international traffic between dengue
endemic countries and those that are usually dengue-free, albeit
permissive for epidemics because of the presence of a suitable
vector (9–11). This is evidenced by recent autochthonous dengue
virus (DENV) transmission in Europe (12, 13) (local transmis-
sion subsequent to importation). The current scale of the public
health problem of dengue highlights the need to better under-
stand the underlying biological and environmental factors that
result in human to mosquito transmission of DENV. A better
comprehension of how these factors vary, and under what con-
ditions, will help us to develop more effective interventions of
DENV transmission.
HUMAN TO MOSQUITO TRANSMISSION OF DENGUE
Transmission of DENV from the human host to mosquitoes
requires multiple biological factors to align in time and space.
Under natural conditions, a susceptible mosquito can only acquire
a DENV infection after it has taken a blood meal from a viremic
person. When viremic blood arrives into the mosquito midgut,
extracellular virus binds to undefined receptors on the cellular
surface of the midgut epithelium. If the virus can successfully
infect and replicate within midgut epithelium cells then new prog-
eny virus are shed into the hemocoel (the cavity in which the
hemolymph circulates, part of the open circulatory system of
invertebrates), where it can subsequently disseminate and infect
secondary tissues, including the salivary glands. Once sufficient
virus replication has occurred in the salivary glands and upon the
next probing/feeding event, the virus may be transmitted to a new
host via the saliva of the infected mosquito.
VECTORS OF DENV
The primary vector of DENV is Aedes aegypti, an endophilic
mosquito, preferring to live in and around homes in tropical
and subtropical regions. This mosquito feeds preferentially on
human blood under field conditions (14), and inhabits tropical
and subtropical climates, with the geographic range spanning all
continents except Antarctica. A secondary dengue vector, Aedes
albopictus, is more exophilic under natural field conditions, com-
monly living outdoors, but still feeds almost exclusively on humans
in Thailand (14), and preferentially on humans in the Indian
Ocean (15). The strong preferences for human blood exhibited by
these mosquitoes increase the potential for disease transmission
among humans.
The expanding geographical range of DENV vectors (16, 17)
underscores our need to examine DENV transmission dynamics
in more detail. In the United States there has been a resurgence of
Aedes aegypti across the South Eastern seaboard, and its presence
has been noted as far north in California as South San Fran-
cisco Bay (W. K. Reisen and M. V. Armijos, UC Davis, personal
communication, August 2013). Aedes aegypti is also expected to
spread beyond its current range within Australia,which is presently
throughout the state of Queensland, extending into the North
Eastern part of Northern Territory (18). Autochthonous cases of
dengue occurred in Portugal (Madeira Islands) in 2012 (13), with
transmission attributed to the invasion of Aedes aegypti in the mid
2000s.
Aedes albopictus, an aggressive, nuisance day-time biter (19),
is now established in numerous areas of Southern Europe (20–
23), with its geographic range having continuously expanded since
its first observation in Albania in 1979 (24). Aedes albopictus has
also become established in parts of South America and Africa
that were previously free of the invasive pest (16) (and references
therein). Its emergence in Australia is also a significant threat (25).
This (potential and actual) range expansion of Aedes albopictus,
www.frontiersin.org June 2014 | Volume 5 | Article 290 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carrington and Simmons Human to mosquito DENV transmission
particularly because it inhabits a more temperate environment
than the tropical Aedes aegypti, may lead to an increased risk
of DENV transmission as it brings a greater number of dengue-
susceptible people into contact with vectors. Photoperiod-induced
diapause and non-desiccating, cold-tolerant eggs further allows
Aedes albopictus to survive in cooler environments for periods of
the year (26, 27).
Other Aedine species have been shown to be capable of trans-
mitting DENV under experimental conditions (28–30), including
Aedes polynesiensis, Aedes scutellaris, and Aedes japonicas. As dis-
cussed in Rosen et al. (28), Aedes polynesiensis has been implicated
in the natural transmission of DENV, but the relative contribution
of each of these mosquitoes to overall transmission has not been
quantified, and is thought to be negligible (31).
HUMAN FACTORS INFLUENCING TRANSMISSION
Factors that influence the transmission of DENV from humans to
mosquitoes include the following.
VIRAL TITER IN HUMAN PLASMA
The amount of virus circulating in the blood of an infected human
will influence the likelihood of a mosquito becoming infected after
a blood meal. Nguyen et al. (32) identified the viremia character-
istics in dengue cases that led to DENV infection of blood-fed
Aedes aegypti. The viremia in humans required to infect 50% of
mosquitoes differed between serotypes (Figure 1). The 50% mos-
quito infectious dose was ~10-fold lower for DENV-1 and DENV-2
(6.29–6.51 log10 RNA copies/ml) than for DENV-3 and DENV-4
(7.49–7.52 log10 RNA copies/ml). A dose–response relationship
was observed such that with an increasing number of DENV RNA
copies, there was an increased likelihood of a mosquito becom-
ing infected, up to the point of saturation. These findings define
the viremia level that interventions such as vaccines and antivi-
rals must target for prevention or amelioration to reduce DENV
transmission.
DURATION OF HUMAN INFECTIOUSNESS
Accumulated data from empirical infection studies on human sub-
jects conducted in the first half of the twentieth century showed
that humans can be infectious to mosquitoes from 1.5 days prior
to the onset of symptoms to around 5 days after the commence-
ment of symptoms (Figure 2) (33–37). In each of these studies,
however, the assignment of the day or hour of the mosquito
FIGURE 1 | Effect of plasma viremia on mosquito susceptibility to
infection (32). With an increasing concentration of DENV in the patient’s
blood, mosquitoes have a higher probability of being infected, as determined
12 days after mosquitoes imbibed the blood meal. Each data point represents
the proportion of DENV-infected mosquitoes after a single blood-feeding
episode. Estimated associations and the 95% confidence intervals are shown
in the blue lines and gray shading, respectively. Image reproduced with
permission from the authors.
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FIGURE 2 | Duration of human DENV infectiousness toAedes
aegypti mosquitoes. A person can become infectious to mosquitoes
up to 1.5 days before the onset of their fever and associated symptoms,
and remain infectious until the end of their febrile period, and sometimes
shortly after. Indicated above the thick black line are the colored arrows
showing the period of human infectiousness for each serotype,
according to Nguyen et al. (32). DENV-1 (shown in blue) and DENV-2 (red)
may be infectious to mosquitoes for up to 2 days after the patient
becomes afebrile, however DENV-3 (green) and DENV-4 (yellow) appear
to be less infectious at these later stages of illness, due to lower plasma
viremia in the patient. A single study (37), found that six dengue patients
were infectious to mosquitoes from 0.25 days, up to a maximum of
1.5 days, before they had any sign of symptoms (indicated by the pale
gray arrow). The serotype of virus used in Siler et al.’s study is unknown.
Below the black line is the relative alignment of the course of dengue
illness. IIP= intrinsic incubation period.
exposures was not systematic [e.g., Cleland et al. (34) exposed
mosquitoes to patients on the 18th, 22nd, 46th, 47th, 57th, 67th,
and 90th hours after the onset of fever (with no apparent pattern
or rationale behind the selection of these time points)], result-
ing in a broad range of exposure time points but with large
gaps in between. In Nguyen et al.’s (32) more recent study, 208
patients who presented to the Hospital for Tropical Diseases in
Ho Chi Minh City, Vietnam were enrolled in the study and ran-
domly assigned to 2 days on which they would be exposed to
naïve mosquitoes. Days of exposure ranged between day 1 and
day 7 of illness. Results demonstrate that a small number of mos-
quitoes can still become infected with each of the four DENV
serotypes up to the sixth day after illness onset. No mosquitoes
became infected after feeding on patients on the seventh day after
onset. Nguyen et al. (32) further demonstrated that patients with
DENV-1 and DENV-2 infections can still be infectious to mos-
quitoes up to 2 days after defervescence, albeit this was rare. For
patients infected with DENV-3 and DENV-4, viremia had declined
below the required infectious dose for mosquitoes to become
infected by this time. In addition, Nguyen et al. (32) demon-
strated that patients with a high early viremia have a greater
probability of having an extended duration of infectiousness. Intu-
itively, a DENV-infected person with a longer duration of viremia
has a greater chance of being bitten by, and infecting, a naïve
Aedes aegypti mosquito. Therefore, patients with a high early
viremia generally have a greater time-window of infectiousness
for mosquitoes.
SYMPTOMATIC VS. ASYMPTOMATIC INFECTIONS
Ambulatory patients with symptomatic DENV infections have
viremia levels that are unquestionably likely to render them infec-
tious to mosquitoes (32). Individuals who are asymptomatic with
a DENV infection also have detectable levels of virus circulating
in the blood (38, 39), but the question remains open as to whether
or not inapparent DENV infections have high enough viremias to
be infectious. Because inapparent DENV infections are common
(40, 41), it follows that they could play a role in the maintenance
of DENV in its natural transmission cycle, should their viremias
be above the infectious threshold level.
UNDERSTANDING THE EXTENT OF DENV TRANSMISSION THAT IS A
RESULT OF ASYMPTOMATIC INFECTIONS
While the estimated number of asymptomatic DENV infections
(over 290 million cases each year) outweighs that of symptomatic
infections around the world (8) the contribution of these asympto-
matic infections to the continued transmission of DENV remains
to be elucidated. Definitive studies to determine whether acute
asymptomatic cases are able to infect susceptible mosquitoes will
give insight to the contribution of asymptomatic infections to the
overall transmission dynamics. These can be done in two ways. The
first involves more detailed surveillance and tracing of contacts of
dengue index cases than that done in current longitudinal stud-
ies [e.g., those in Thailand (40), Nicaragua (41), and Peru (42)].
Increasing the frequency of blood draws of these contacts will help
to identify asymptomatic cases at the earliest possible time. At first
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observation of viremia, the individual can be exposed to suscep-
tible mosquitoes that are then tested for infection after a suitable
incubation period.
Alternatively, we can gain this same knowledge in human chal-
lenge experiments, along with vast amounts of other information,
on early infection dynamics (the portion of dengue pathogenesis
that is least understood because patients only present to health
care professionals after symptoms have already manifested). In
human challenge studies, some participants will likely develop
asymptomatic infections and the question of whether these indi-
viduals are infectious to mosquitoes can be tested in a controlled
setting. In addition, such studies should also take such an oppor-
tunity to study the early infection dynamics in the participants
in human challenge experiments with the aim in investigat-
ing the determinants of an infection becoming symptomatic or
asymptomatic.
To date, there are few studies that have even demonstrated that
asymptomatic infections result in a detectable viremia. Studies in
both Nicaragua and Indonesia have described persons with acute
asymptomatic DENV-1 and DENV-2 infections (having success-
fully amplified viral RNA by RT-PCR and/or by directly isolating
the virus from the blood draw) using an index-case cluster sur-
veillance approach described above (38, 39). This demonstrates
it is indeed possible to study asymptomatic infections within the
human host, but unfortunately in both studies, DENV viremia was
not quantified, and mosquitoes were not exposed to the blood of
these subjects, thus it is unknown if these individuals were infec-
tious. Duong et al. (43) reported the first and only quantification
of viremias in asymptomatic cases in the literature, however, these
investigators did not assess infectiousness to mosquitoes. Until
empirical evidence is obtained that supports the fact that mosqui-
toes can become infected, and infectious, after directly feeding on
asymptomatic DENV infections, one cannot ascertain the extent
to which these many millions of clinically silent infections are
contributing to ongoing DENV transmission, or whether they are
effectively dead-end hosts.
MOSQUITO SUSCEPTIBILITY TO INFECTION
Vector competence (VC) assays of mosquito susceptibility to
DENV frequently test some combination of mosquito infection,
dissemination, and onward transmission of virus. One factor
potentially influencing our estimates of VC is that many studies
have used artificially derived infectious blood meals to orally infect
mosquitoes. In the first half of the twentieth century, mosquitoes
were routinely fed on people suffering from dengue (33, 34, 36, 37,
44–48). When the weight of DENV research began to take place
in non-endemic countries, a need for alternative methods arose.
Since then, ordinarily, studies infect mosquitoes using artificial
blood meals, consisting of a non-human blood source (often being
derived from rabbit or pig), spiked with infectious virus grown
in cell culture. While there are benefits of feeding mosquitoes
using artificial blood meals (e.g., larger numbers of mosquitoes can
be used, viral titers within the blood meal can be manipulated),
employing the natural transmission mode to infect mosquitoes
will help better describe the three-way human–mosquito–virus
relationship in nature. Recognized factors influencing the VC of
Aedes aegypti for DENV transmission are described below.
RELATIVE VECTOR COMPETENCE OF AEDES AEGYPTI AND AEDES
ALBOPICTUS
Although Aedes aegypti are generally considered to be the pri-
mary vectors of DENV, Aedes albopictus have been implicated as
the primary, if not the sole vector of DENV during some disease
outbreaks (49, 50). Empirical studies show the two species do not
differ in the competence to transmit DENV; both Aedes aegypti and
Aedes albopictus collected from multiple sites within Cameroon
showed no overall difference in their disseminated infection rate to
DENV-2 (the same held true for infection with chikungunya virus
also) (50). Similar results failing to identify differences in compe-
tence between the two species were reported for mosquitoes from
the Florida Keys challenged with DENV-1 (51). Although both of
these studies used artificial blood meals when infecting the mos-
quitoes and obtained similar results, the relative competence of
these species after feeding on the viremic blood of a dengue case
is unknown. A meta-analysis of 14 studies on the relative suscep-
tibility of Aedes albopictus and Aedes aegypti suggests that Aedes
albopictus are more susceptible to midgut infections than Aedes
aegypti; however, the ability of the virus to disseminate in the latter
mosquito is greater, suggesting a greater potential for transmission
in nature (52).
VIRUS CONCENTRATION IN THE BLOOD MEAL AND THE EXTRINSIC
INCUBATION PERIOD
Numerous studies demonstrate that the proportion of mosquitoes
that become infected with DENV depends on the concentration
of virus in the blood meal (32, 53). Bennett et al. (53) identi-
fied a positive association between viral titer of DENV-2 in the
infectious blood meal and the proportion of Aedes aegypti with an
infected midgut. Once infected, however, rates of dissemination
in the same mosquitoes showed no such association. As described
in more detail above, in more than 200 patients with naturally
acquired DENV infections, Nguyen et al. (32) detected a positive
correlation between mosquito infection prevalence and the titer
of virus in human blood (Figure 1), consistent across all four
serotypes.
Viral titer can also influence the time that it takes for a mos-
quito to become infectious. Watts et al. (54) demonstrated that
infecting Thai Aedes aegypti with a low titer of virus resulted in
an extended period (up to 25 days) before the mosquitoes were
able to transmit DENV-2 to naïve rhesus monkeys, compared to
when using a higher titer of virus, where it took only 12 days after
incubation at the same holding temperature of 30°C.
ENVIRONMENTAL TEMPERATURE
Environmental temperature has long been implicated in altering
mosquito VC to transmit viruses. A positive correlation between
mean exposure temperature and the proportion of mosquitoes
that become infected with the virus exists, that is bound by upper
and lower limits (54–56). The lower the temperature, the longer
it takes for the virus to replicate to high enough concentrations to
be transmissible (and be detectable using laboratory techniques),
but at high temperatures virus replication rates are greater, and
the minimum time for the mosquito to complete the extrinsic
incubation is decreased. Some populations differ in these values,
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but estimates for minimum and maximum thresholds for trans-
mission (i.e., the temperature at which a mosquito can become
infectious) at constant temperatures are around 13°C at the lower
end (55), and 35°C at the upper end (54, 56) for Aedes aegypti
mosquitoes (although higher temperatures are not known to have
been tested). It is not known what these upper and lower limits
are for Aedes albopictus.
Testing of the upper thresholds proves difficult, because after
mosquitoes have been reared at such high temperatures (cf. 38°C
and above) the lifespan of the mosquito is reduced due to the neg-
ative effect of the high heat; their flight activity is almost negligible
and they are unable to source a blood meal (57). Therefore, assess-
ing VC at such high temperatures must be performed at least in
semi-unnatural conditions (offering the blood meal to the mos-
quitoes while at a cooler temperature and then placing them back
at the exposure temperatures).
Several recent VC studies investigating transmission of
mosquito-borne pathogens have also shown that using natural
temperature exposures (ones that fluctuate throughout the day,
as a mosquito experiences in nature as opposed to constant tem-
peratures) can alter the expected VC of a mosquito population
(56, 58–60). Reaction norms for VC (and other life-history traits)
as characterized under constant temperatures failed to accurately
predict the competence of Aedes aegypti for DENV transmis-
sion, after exposure to the same mean temperature, but with
the addition of daily temperature fluctuations. Large fluctuations
in the order of ~19°C around a low mean temperature of 20°C
were shown to increase the number of Aedes aegypti that became
infected with DENV-1, and accelerated the time that it took for dis-
semination to occur (by around 10 days) (56). Conversely, around
a mean temperature of 26°C, one that is commonly used for
laboratory-based experiments, the same magnitude of fluctuations
had the opposite effect; there were fewer mosquitoes that devel-
oped a disseminated infection, and the first time dissemination
observed was extended by 4 days (60). These studies highlight that
it is important to empirically test mosquitoes under conditions
representative of their natural environment to accurately measure
VC used for modeling purposes.
Humidity changes may also play a role in mosquito VC, but
precise measurements under variable humidity regimes have not
been made. It is known that desiccation under dry conditions
can place mosquitoes under stress. This stress may exacerbate the
inability of the mosquito to fight off a viral infection, or indeed,
may negatively impact the virus, because the mosquito may uti-
lize available cellular resources for their maintenance before the
virus has the opportunity to use them. At least in Aedes albopictus,
changes in humidity can enhance the effect of changes in temper-
ature affecting mosquito fecundity (61), and it follows that this is
surmised to be the same in the closely related Aedes aegypti. More
in-depth studies are required to elucidate the effect of humidity
on VC indices.
POPULATION EFFECTS, AND INTERACTIONS BETWEEN VIRAL AND
MOSQUITO GENOTYPES
Populations of mosquitoes reportedly vary in their susceptibility
to DENV infection (53, 62, 63), which can alter the accuracy of
predictions of transmission dynamics among populations. On a
large geographic scale,Gubler et al. (62) demonstrated population-
specific differences in the ability of mosquitoes to become infected
with each of the four DENV serotypes. Between populations, there
were consistent patterns of high and low infection when exposed
to each of the serotypes, suggesting that the factors controlling
infection by each of the DENV serotypes is uniform and possi-
bly conserved. Even on a relatively small scale, Bennett et al. (53)
found that there was significant variation in the ability of 24 pop-
ulations of mosquitoes from Mexico and USA to become infected
with a DENV-2 strain.
There is also the suggestion that within a single population
of mosquitoes, susceptibility to infection by different viral iso-
lates/genotypes may vary (64–66). After challenging three isofe-
male lines of Aedes aegypti that were derived from Ratchaburi,
Thailand, with three Thai isolates of DENV-1 virus (that were in
current circulation), Lambrechts et al. (64) demonstrated that each
of the Ratchaburi isofemale lines were most susceptible to infec-
tion by the viral isolate from the same city, Ratchaburi, as opposed
to those from Kamphaeng Phet or Bangkok. A follow-on study
identified polymorphisms at the dicer-2 locus as being associated
with these phenotypic differences in mosquito VC. Further studies
demonstrating that this result holds true for mosquitoes derived
from other populations are needed to show the generality of the
phenomenon. In any case, the differences demonstrated between
mosquito populations in their susceptibility to DENV infections
suggest that mathematical models of DENV transmission need to
consider the nuances of specific mosquito–virus interactions in
their parameterization.
BLOOD-FEEDING BEHAVIOR AND PREFERENCES OF DENV MOSQUITO
VECTORS
One of the challenges standing in the way of developing targeted
intervention approaches for the mosquito to human transmis-
sion cycle include a lack of understanding of mosquito behaviors,
including that of host-seeking. A cornerstone of the DENV trans-
mission cycle is the mosquito vector, and without an infected
mosquito’s success in seeking a suitably DENV-naïve host, trans-
mission would cease and the virus would die. Since other bacteria
and viruses manipulate the biology and behavior of their hosts
to facilitate their own transmission (67, 68), it is plausible that
DENV may do the same. Studies on the blood-feeding behavior
of DENV-infected mosquitoes have examined duration of prob-
ing and feeding (69, 70), transmission efficiency during probing
(71), and motivation and avidity to feed (72). While DENV infec-
tions may increase the duration of feeding and the likelihood of
re-feeding after interruption (as tested using either mice or guinea
pigs), no studies have directly investigated human host-seeking
ability.
Hypothetically, if an uninfected mosquito is potentially
attracted to human hosts with a high body temperature (e.g., as a
result of fever), does DENV then manipulate the physiology of an
infected mosquito to be more attracted to people with lower body
temperature (e.g., those that are likely to be uninfected) for their
subsequent meals, to increase the likelihood of transmission? Can
DENV increase the frequency and/or desire to blood feed, leading
to mosquito vectors feeding on multiple hosts, thereby enhanc-
ing transmission? Finally, does the virus alter the physiology of
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the human host (other than causing high fever) in ways that are
detectable to a mosquito, making them more attractive? Inves-
tigating the host-feeding preferences and host-seeking ability of
infected and uninfected mosquitoes can help elucidate the extent
to which DENV manipulates its mosquito vectors.
OTHER FACTORS INFLUENCING INFECTION
Mosquitoes have an increased risk of infection when exposed to
naturally infected dengue patients when they have a high tympanic
temperature and high plasma viremia (32). With the progression
of illness in a patient, IgM and IgG titers continue to increase until
after viremia declines beyond a detectable limit. With this increas-
ing day of illness and associated IgM and IgG titers, Aedes aegypti
experience a decreasing risk of DENV infection (32). Increased
titers of these antibodies in the blood may directly influence mos-
quito susceptibility, by neutralizing virus and preventing infection
of the midgut.
NOVEL ENTOMOLOGICAL STRATEGIES FOR REDUCING DENV
TRANSMISSION IN THE FIELD
A number of novel strategies are being developed that control
mosquito populations. These include but are not limited to the
use of genetic manipulations of mosquitoes, fungus, and bacte-
ria to curb pathogen transmission. The RIDL (release of insects
carrying a dominant lethal) technique releases genetically mod-
ified males into a mosquito population that carry a late-acting
lethal, development gene that is transmitted to each of its progeny
(73). Fungal biopesticides have also been proposed for control of
mosquito transmission of pathogens (74).
Another of these strategies intends to release mosquitoes
infected with the intracellular bacterium Wolbachia pipientis (75,
76). In Aedes aegypti, Wolbachia manipulate the host reproduction
system to enhance its own vertical transmission between genera-
tions, but can also reduce host lifespan (77), and critically interfere
with DENV replication (78). The level of virus interference in
Aedes aegypti is however dependent on the bacterial strain.
Releasing mosquitoes into the wild that contain this intra-
cellular bacterium aims to reduce the ability of mosquitoes to
transmit DENV under field conditions. After the initial estab-
lishment phase of the release, this biological control strategy is
self-maintained due to Wolbachia’s ability to drive itself into a
population of hosts, thereby increasing the benefit of this strat-
egy by decreasing long-term maintenance costs. Additionally, the
technology can be implemented relatively cheaply, meaning that
countries that face a large dengue burden may see the greatest value
in its implementation. There are also multiple strains of the bacte-
ria that can be utilized, with different incompatibility phenotypes,
offering the opportunity for multiple releases. Field releases of
Wolbachia-infected Aedes aegypti have already occurred in North-
ern Australia, Vietnam, and Indonesia with the aim of suppressing
DENV transmission.
One theoretical concern about this strategy is the long-term
efficacy of the program due to evolutionary changes in the
genomes of vector, virus, and/or bacteria. Evolution may erode
the viral replication inhibition effect of the bacteria, increased vir-
ulence of the virus in humans, and decrease the life-shortening
phenotype in the bacterial host, as seen in the native Drosophila
host of the life-shortening Wolbachia strain (79). An objective dis-
cussion of the potential evolutionary changes in the Wolbachia vs.
DENV relationship, within the human–Aedes aegypti framework,
is presented by Bull and Turelli (80).
SUMMARY AND RESEARCH PRIORITIES
The successful transmission of DENV from human to mosqui-
toes is a complex interplay of biotic and abiotic factors. Despite
this, DENV transmission occurs on a global scale and continues
to be the most prevalent arbovirus infection, with an estimated
390 million infections each year (8). At this point, there are sev-
eral research priorities that would benefit our understanding of
human to mosquito transmission, and subsequently aid research
and development into the long-term goal of finding effective tools
for DENV prevention (e.g., vaccines, prophylactic or therapeutic
use of antivirals, and vector control). These research priorities are:
(1) To what extent do asymptomatic infections contribute to
ongoing transmission? What proportion of asymptomatic
infections result in mosquitoes being capable of transmis-
sion? What is the range of viremia required for transmission
to occur?
(2) Can antivirals and/or neutralizing antibodies be administered
to dengue patients to reduce the potential for DENV patients
to infect naïve mosquitoes? Can antibodies neutralize the virus
in the mosquito before it becomes infected? How would this
feasibly be administered?
(3) How will dengue vaccines modify viremia after natural expo-
sure? Will they modify viremia to a level that prevents human
to mosquito transmission?
(4) What preferences do Aedes mosquitoes show toward febrile
and non-febrile hosts? Are naïve mosquitoes more attracted
to febrile hosts (infected with any arbovirus)? Does DENV
manipulate host-seeking behavior in infected mosquitoes?
(5) Can the likely field success of novel dengue control mea-
sures, such as Wolbachia, be predicted from laboratory studies?
Which of the many and complex effects of Wolbachia on Aedes
aegypti life-history traits have the greatest impact on VC?
Advances in our understanding of the DENV transmission cycle
in humans and mosquitoes should support the rational develop-
ment and application of interventions such as vaccines, antivirals,
and novel entomological control measures.
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